Department of Biomedical Engineering, School of Medicine, Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh City, 700000, Vietnam.
Research Center for Genetics and Reproductive Health (CGRH), School of Medicine, National University HCMC, Ho Chi Minh City, 700000, Vietnam.
Sci Rep. 2023 Jan 27;13(1):1495. doi: 10.1038/s41598-023-28140-y.
Recent therapeutic advances in breast cancer (BC) have improved survival outcomes; however, the prognosis for patients with bone metastasis (BM) remains poor. Hence, novel clinical biomarkers are needed to accurately predict BC BM as well as to promote personalized medicine. Here, we discovered a novel biomarker, TOR1B, for BM in BC patients via analysis of BC gene expression data and clinical information downloaded from open public databases. In cancer cells, we found high expression levels of TOR1B in the nucleus and endoplasmic reticulum. Regarding gene expression, the level of TOR1B was significantly upregulated in BC patients with BM (p < 0.05), and the result was externally validated. In addition, gene expression clearly demonstrated two distinct types of prognoses in ER- and PR-positive patients. In multivariate regression, the gene could be an independent predictor of BM in BC patients, i.e., a low expression level of TOR1B was associated with delayed metastasis to bone in BC patients (HR, 0.28; 95% CI 0.094-0.84). Conclusively, TOR1B might be a useful biomarker for predicting BM; specifically, patients with ER- and PR-positive subtypes would benefit from the clinical use of this promising prognostic biomarker.
近年来，乳腺癌（BC）的治疗进展改善了患者的生存预后；然而，骨转移（BM）患者的预后仍然较差。因此，需要新的临床生物标志物来准确预测 BC BM，并促进个体化医学。在这里，我们通过分析从公开数据库下载的 BC 基因表达数据和临床信息，发现了一种新的 BC 患者 BM 的生物标志物 TOR1B。在癌细胞中，我们发现 TOR1B 在核和内质网中高表达。在基因表达方面，BM 患者的 TOR1B 水平显著上调（p<0.05），并且该结果经过了外部验证。此外，基因表达清楚地表明 ER-和 PR-阳性患者有两种不同的预后类型。在多变量回归中，该基因可以作为 BC 患者 BM 的独立预测因子，即 TOR1B 低表达与 BC 患者骨转移延迟相关（HR，0.28；95%CI 0.094-0.84）。总之，TOR1B 可能是预测 BM 的有用生物标志物；具体来说，ER-和 PR-阳性亚型的患者将受益于这种有前途的预后生物标志物的临床应用。
